MAYNE PHARMA GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.37 AUD | +1.92% |
|
-10.53% | +3.58% |
| 05-10 | Mayne Pharma Group's Nextstellis Oral Contraceptive Receives Two Additional US Patents | MT |
| 02-26 | Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15% | MT |
| Sales 2024 * | 383M 256M 20.17B | Sales 2025 * | 426M 285M 22.43B | Capitalization | 517M 346M 27.25B |
|---|---|---|---|---|---|
| Net income 2024 * | -88M -58.92M -4.64B | Net income 2025 * | -19M -12.72M -1B | EV / Sales 2024 * | 1.14 x |
| Net cash position 2024 * | 79.89M 53.49M 4.21B | Net cash position 2025 * | 53.05M 35.52M 2.8B | EV / Sales 2025 * | 1.09 x |
| P/E ratio 2024 * |
-5.88
x | P/E ratio 2025 * |
-26.2
x | Employees | 967 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.67% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mayne Pharma Group Limited
More press releases
| 1 day | +1.92% | ||
| 1 week | -10.53% | ||
| Current month | -8.61% | ||
| 1 month | -6.32% | ||
| 3 months | +20.64% | ||
| 6 months | +36.70% | ||
| Current year | +3.58% |
1 week
5.94
7.20
1 month
5.947.46
Current year
5.007.46
1 year
2.757.46
3 years
0.228.50
5 years
0.2212.90
10 years
0.2242.20
| Managers | Title | Age | Since |
|---|---|---|---|
Shawn O'Brien
CEO | Chief Executive Officer | - | 30/09/22 |
Aaron Gray
DFI | Director of Finance/CFO | - | 28/08/22 |
Keith Moore
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Frank Condella
CHM | Chairman | 70 | 29/05/18 |
Patrick Blake
BRD | Director/Board Member | 59 | 27/06/18 |
Shawn O'Brien
CEO | Chief Executive Officer | - | 30/09/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/05/24 | 6.37 | +1.92% | 221 592 |
| 16/05/24 | 6.25 | +2.46% | 676,149 |
| 15/05/24 | 6.1 | -8.41% | 285,874 |
| 14/05/24 | 6.66 | -5.80% | 759,072 |
| 13/05/24 | 7.07 | +0.86% | 72,172 |
Delayed Quote Australian S.E., May 17, 2024 at 07:10 am
More quotes
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Companyâs segments include Womenâs Health, Dermatology, and International. The Womenâs Health segment distributes womenâs health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.
Sector
Pharmaceuticals
Calendar
22/08/2024
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.37
AUD
Average target price
6.89
AUD
Spread / Average Target
+8.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.58% | 339M | |
| +21.59% | 44.15B | |
| +23.03% | 23.02B | |
| +18.22% | 15.33B | |
| +12.26% | 13.74B | |
| +52.55% | 12.16B | |
| -10.02% | 6.84B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.88% | 5.66B |
- Stock Market
- Equities
- MYX Stock
